| Literature DB >> 32774888 |
Jose Luis Vallejo-Garcia1, Mary Romano1,2, Luca Pagano1,3, Alessio Montericcio1, Alfredo Borgia1, Emanuela Morenghi1, Paolo Vinciguerra1.
Abstract
BACKGROUND: We reviewed our experience in the management of cataract and idiopatic epiretinal membrane surgeries at the Humanitas Research Institute-Milan, Italy- over the past 3 years.Entities:
Keywords: Cataract surgery; Epiretinal membrane; Peeling; Retina
Year: 2020 PMID: 32774888 PMCID: PMC7401209 DOI: 10.1186/s40942-020-00239-8
Source DB: PubMed Journal: Int J Retina Vitreous ISSN: 2056-9920
Preoperative population characteristics
| N | 57 |
|---|---|
| Age (years) | 71.6 ± 5.3 |
| BCVA | 0.46 ± 0.18 |
| ERM staging | 2.48 ± 0.79 |
| 1 | 5 (8.9%) |
| 2 | 24 (42.9%) |
| 3 | 22 (39.3%) |
| 4 | 5 (8.9%) |
| CMT (µm) | 443 ± 79 |
| MV (mm3) | 11.9 ± 1.4 |
| CME | 13 (22.8%) |
| IS/OS disruption | 8 (14.0%) |
| NSD | 3 (5.3%) |
Pre and 1-Month post cataract surgery values
| Pre | Post | P | |
|---|---|---|---|
| BCVA | 0.46 ± 0.18 | 0.45 ± 0.18 | 0.4605 |
| CMT (µm) | 443 ± 79 | 486 ± 99 | < 0.0001 |
| MV (mm3) | 11.9 ± 1.4 | 12.4 ± 1.8 | < 0.0001 |
| CME | 13 (22.8%) | 32 (56.1%) | < 0.0001 |
| IS/OS | 8 (14.0%) | 16 (28.1%) | 0.0047 |
| NSD | 3 (5.3%) | 9 (15.8%) | 0.0143 |
Association with variation of BVCA
| Coefficient (95% CI) | P | |
|---|---|---|
| Age | −0.001 (−0.023–0.021) | 0.906 |
| Diabetes | −0.070 (−0.399–0.259) | 0.670 |
| ERM staging | 0.058 (−0.092–0.206) | 0.448 |
| CMT (µm) | −0.000 (−0.002–0.001) | 0.847 |
| MV (mm3) | 0.015 (−0.068–0.099) | 0.713 |
| CME | 0.128 (−0.143–0.398) | 0.349 |
| IS/OS | 0.247 (−0.075–0.570) | 0.130 |
| NSD | −0.095 (−0.607–0.417) | 0.711 |
Different variables in diabetic and non-diabetic groups
| DM | No DM | OR (95% CI) | P | |
|---|---|---|---|---|
| N eyes | 8 | 49 | ||
| Age | 72.8 ± 8.2 | 71.4 ± 4.7 | 1.05 (0.91–1.21) | 0.502 |
| Gender (M) | 6 (75.0%) | 24 (49.0%) | 3.13 (0.57–17.03) | 0.188 |
| ERM staging | 2.29 ± 0.95 | 2.51 ± 0.77 | 0.68 (0.24–1.94) | 0.478 |
| BCVA | 0.40 ± 0.18 | 0.47 ± 0.18 | 0.11 (0.00–6.07) | 0.277 |
| CMT (μm) | 381 ± 72 | 452 ± 77 | 0.98 (0.97–1.00) | 0.020 |
| MV (mm3) | 12.2 ± 1.8 | 11.8 ± 1.3 | 1.19 (0.70–2.01) | 0.525 |
| CME | 2 (25.0%) | 11 (22.5%) | 1.15 (0.20–6.53) | 0.873 |
| IS/OS | 1 (12.5%) | 7 (14.3%) | 0.86 (0.09–8.07) | 0.893 |
| NSD | 2 (25.0%) | 1 (2.0%) | 16.0 (1.25–204) | 0.033 |
Fig. 1OCT showing a stage 2 ERM pre (left) and post (right) phacoemulsification. It can be observed a slight increase in the CME
Fig. 2OCT showing a stage 3 ERM pre (left) and post (right) phacoemulsification. It can be observed a significant increase in the CME and a small subfoveal NSD